CA3142073A1 - Recombinant herpes simplex virus for cancer immunotherapy - Google Patents
Recombinant herpes simplex virus for cancer immunotherapy Download PDFInfo
- Publication number
- CA3142073A1 CA3142073A1 CA3142073A CA3142073A CA3142073A1 CA 3142073 A1 CA3142073 A1 CA 3142073A1 CA 3142073 A CA3142073 A CA 3142073A CA 3142073 A CA3142073 A CA 3142073A CA 3142073 A1 CA3142073 A1 CA 3142073A1
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- hsv
- protein
- cells
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862682202P | 2018-06-08 | 2018-06-08 | |
| US62/682,202 | 2018-06-08 | ||
| PCT/US2019/035922 WO2019236931A1 (en) | 2018-06-08 | 2019-06-07 | Recombinant herpes simplex virus for cancer immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3142073A1 true CA3142073A1 (en) | 2019-12-12 |
Family
ID=67070913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3142073A Pending CA3142073A1 (en) | 2018-06-08 | 2019-06-07 | Recombinant herpes simplex virus for cancer immunotherapy |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12329794B2 (https=) |
| EP (1) | EP3801583B1 (https=) |
| JP (1) | JP7373209B2 (https=) |
| KR (1) | KR102906757B1 (https=) |
| CN (1) | CN112243378B (https=) |
| AU (1) | AU2019282755B2 (https=) |
| CA (1) | CA3142073A1 (https=) |
| WO (1) | WO2019236931A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111635913B (zh) * | 2020-06-16 | 2022-03-04 | 广东东阳光药业有限公司 | 构建体及其应用 |
| CN113862229A (zh) * | 2020-06-30 | 2021-12-31 | 东莞市东阳光生物药研发有限公司 | 一种重组单纯疱疹病毒及其构建方法 |
| CN113943752A (zh) * | 2020-07-15 | 2022-01-18 | 东莞市东阳光生物药研发有限公司 | 构建体、敏感性提高的溶瘤病毒及其应用 |
| CN114075574A (zh) * | 2020-08-19 | 2022-02-22 | 广东东阳光药业有限公司 | 构建体、溶瘤病毒及其应用 |
| TW202521570A (zh) * | 2023-08-25 | 2025-06-01 | 大陸商勃林格殷格翰動物保健（中國）有限公司 | 用於禽類疫苗的新型ｄｅｖ載體 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60115600T2 (de) * | 2000-01-21 | 2006-07-20 | Biovex Ltd. | Virusstämme für die onkolytische behandlung von krebs |
| US7264814B2 (en) * | 2001-05-09 | 2007-09-04 | M's Science Corporation | Composition and method for treating cancer using herpes virus |
| GB0714578D0 (en) * | 2007-07-26 | 2007-09-05 | Crusade Lab Ltd | Viruses |
| ES2861450T3 (es) | 2015-07-20 | 2021-10-06 | Virttu Biologics Ltd | Uso del virus del herpes simple oncolítico en combinación con un inhibidor de puntos de control inmunitario, en el tratamiento del cáncer |
| US20170319638A1 (en) | 2016-05-06 | 2017-11-09 | Virttu Biologics Limited | Treatment of cancer |
-
2019
- 2019-06-07 US US17/054,338 patent/US12329794B2/en active Active
- 2019-06-07 AU AU2019282755A patent/AU2019282755B2/en active Active
- 2019-06-07 CA CA3142073A patent/CA3142073A1/en active Pending
- 2019-06-07 CN CN201980038180.3A patent/CN112243378B/zh active Active
- 2019-06-07 KR KR1020207033859A patent/KR102906757B1/ko active Active
- 2019-06-07 EP EP19733912.0A patent/EP3801583B1/en active Active
- 2019-06-07 JP JP2020568472A patent/JP7373209B2/ja active Active
- 2019-06-07 WO PCT/US2019/035922 patent/WO2019236931A1/en not_active Ceased
-
2025
- 2025-05-23 US US19/216,880 patent/US20250339482A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250339482A1 (en) | 2025-11-06 |
| CN112243378A (zh) | 2021-01-19 |
| WO2019236931A1 (en) | 2019-12-12 |
| AU2019282755B2 (en) | 2025-09-11 |
| US20210138009A1 (en) | 2021-05-13 |
| EP3801583A1 (en) | 2021-04-14 |
| AU2019282755A1 (en) | 2021-01-28 |
| KR20210022547A (ko) | 2021-03-03 |
| US12329794B2 (en) | 2025-06-17 |
| KR102906757B1 (ko) | 2025-12-31 |
| EP3801583B1 (en) | 2025-07-02 |
| JP7373209B2 (ja) | 2023-11-02 |
| CN112243378B (zh) | 2024-12-31 |
| JP2021527072A (ja) | 2021-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250339482A1 (en) | Recombinant Herpes Simplex Virus for Cancer Immunotherapy | |
| Manservigi et al. | HSV recombinant vectors for gene therapy | |
| Bai et al. | A review of HSV pathogenesis, vaccine development, and advanced applications | |
| CA3014504A1 (en) | Smc combination therapy for the treatment of cancer | |
| Nguyen et al. | The current state of oncolytic herpes simplex virus for glioblastoma treatment | |
| Scanlan et al. | Herpes simplex virus 1 as an oncolytic viral therapy for refractory cancers | |
| JPH10501990A (ja) | 複製能力のある単純ヘルペスウイルスは新生細胞の破壊を媒介する | |
| Zhang et al. | Construction of an IL12 and CXCL11 armed oncolytic herpes simplex virus using the CRISPR/Cas9 system for colon cancer treatment | |
| US20220056481A1 (en) | M2-defective poxvirus | |
| US7514252B2 (en) | Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression | |
| EP1212428B1 (en) | Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression | |
| WO2019043282A1 (es) | Producto de combinación que comprende una célula madre mesenquimal modificada y una sustancia antigénica | |
| US20030228281A1 (en) | Use of mutant herpes viruses and anticancer agents in the treatment of cancer | |
| JP2024512053A (ja) | 転写及び翻訳の二重調節を受ける腫瘍溶解性単純ヘルペスウイルスベクター | |
| US20250161384A1 (en) | Transcriptional and translational dual regulated oncolytic herpes simplex virus vectors | |
| RU2819245C2 (ru) | M2-дефектный поксвирус | |
| Froechlich | Dissecting the STING-dependent molecular mechanisms in a preclinical model of combined treatment with tumour-targeted Herpes simplex virus and immune checkpoint blockade | |
| Watson | Characterizing a novel viral sensitizer BI-D1870 | |
| Beauregard | Type I Interferon-Mediated Killing of Cancer Cells with IAP-Targeted Combination Immunotherapy | |
| Wongthida | Understanding, and exploiting, the contribution of the immune system to the therapeutic efficacy of oncolytic virotherapy with vesicular stomatitis virus (VSV) | |
| Baird | Development of a Novel Model for Exploring the Role of Regulatory T-cells in Oncolytic HSV Cancer Therapy | |
| Rodrigues | Characterization of Oncolytic Herpesviruses | |
| EP1486212A1 (en) | Combination of a mutant herepes virus and irinotecan for the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230606 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240729 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED Effective date: 20241119 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241119 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT Effective date: 20250121 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250121 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250121 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250505 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250507 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250507 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250513 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250513 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251217 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260306 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260317 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260317 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260317 |